Pharmacokinetics and Safety of DWJ1451 in Healthy Adults

An Open-label, Randomized, 2x2 Crossover Study to Compare the Pharmacokinetics and Safety Following Administration of DWJ1451 and Co-administration of DWC202008 and DWC202009 in Healthy Volunteers

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04819932

Enrollment

Registered

2021-03-29

Start date

2021-03-13

Completion date

2021-04-02

Last updated

2021-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

Amlodipine, olmesartan, total ezetimibe, rosuvastatin AUCt, Cmax

Interventions

DRUGDWJ1451

DWC202008 DWC202009

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Age 19 to 55 years * Healthy Adult

Exclusion criteria

* Non-Healthy

Design outcomes

Primary

Measure	Time frame	Description
Pharmacokinetic parameter of DWJ1451:AUC0-t	0 - 72 hours after dosing	Area under the plasma xonxentration-time curve from time 0 to t
Pharmacokinetic parameter of DWJ1451:Cmax	0 - 72 hours after dosing	Maximum plasma drug concentration

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026